[Transplantation of normal or genetically modified myoblasts for the treatment of hereditary or acquired diseases].
The clinical trials of myoblast transplantation in Duchenne Muscular Dystrophy (DMD) patients produced disappointing results. The main problems responsible for these poor results have since then been identified and partially resolved. One of them was related to the use of an inadequate immunosuppression and, since then, immunosuppression with FK506 has permitted successful myoblast transplantation not only in mice but also in monkeys. The requirement for a sustained immunosuppression may be eventually avoided by developing a state of tolerance to the allogeneic cells or by autologous transplantation of genetically corrected myoblasts or stem cells. The rapid death of 75-80% of the injected myoblasts during the first five days has also contributed to the limited success of the early trials. This death was due to an inflammatory reaction and has been compensated in animal experiments by the injection of a larger number of cells (30 millions per cc). Finally, the myoblasts migrated only 0.5 mm away from their site of injection. This problem is currently compensated in animal experiments by injecting the myoblasts at every mm. The number of injections required may eventually be reduced by transfecting myoblasts with one or several metalloproteinase genes. The very good results obtained during the last two years in primates permit us to undertake a new phase I clinical trial to verify that myoblast transplantation can lead to the formation of muscle fibers expressing normal dystrophin in muscles of DMD patients.
Tremblay
J P
JP
Unité de Génétique Humaine, Centre de Recherche du Centre Hospitalier de l'Université Laval, 2705 boul. Laurier, Ste Foy, P.Q., Canada G1V4G2. Jacques-P.Tremblay@crchul.ulaval.ca
Vilquin
J T
JT
D000818:Animals; D017690:Cell Transplantation; D016922:Cellular Senescence; D002986:Clinical Trials as Topic; D006082:Graft Enhancement, Immunologic; D006085:Graft Survival; D000882:Haplorhini; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007108:Immune Tolerance; D007165:Immunosuppression Therapy / Q000009:adverse effects / Q000379:methods; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008666:Metalloendopeptidases / Q000235:genetics; D051379:Mice; D018101:Mice, Inbred mdx; D015778:Minor Histocompatibility Antigens / Q000276:immunology; D018482:Muscle, Skeletal / Q000166:cytology* / Q000276:immunology; D009135:Muscular Diseases / Q000235:genetics / Q000628:therapy; D009136:Muscular Dystrophies / Q000628:therapy*; D009137:Muscular Dystrophy, Animal / Q000628:therapy; D016559:Tacrolimus / Q000627:therapeutic use; D014162:Transfection; D017211:Treatment Failure
D007166:Immunosuppressive Agents; D015778:Minor Histocompatibility Antigens; D008666:Metalloendopeptidases; D016559:Tacrolimus
La transplantation de myoblastes normaux ou génétiquement modifiés pour le traitement de maladies héréditaires ou acquises.